Global In-Vitro Diagnostics Market estimated to grow at CAGR of 6.2% (2019 - 2026)

DataM Intelligence announces its market report titled “Global In-Vitro Diagnostics Market – Size, Share and Forecasts (2019-2026)” which reflects the size, share, forecast analysis of key players. The report worldwide analyses market drivers and restraints to provide market opportunities.

The market is driven by increasing prevalence of various diseases and raising awareness for diagnosis among consumers. The growth in the market is further supported by developments such as portable and point-of-care testing equipment.
By Application, Infectious diseases have the largest share with a market share of approximately 40% of the global market, followed by oncology and diabetes. By End User, hospitals have the predominant share of almost 50% of the global IVD market.
By Geography, North America accounted for the largest segment of the global IVD market followed by Europe with 31% of the global market in 2018.
Get a free sample of the report -https://www.datamintelligence.com/research-report/in-vitro-diagnostics-market
Global In-Vitro Diagnostics Market Dynamics
Personalized medicines or treatment improves the access and clinical development of various diagnostic procedures. Personalized medicine is still relatively in the nascent stages as compared to conventional medical treatments. However various companies are increasingly offering personalized medicine. A cancer diagnosis is a prominent field for personalized medicines. Genome sequencing of a tumour can be a useful tool, but cancer cells have the ability to mutate and change its genome quickly executing an ineffective treatment. Which lead doctors to revert back to more traditional treatment systems. Companies such as Sartorius that has expertise in the production of specific, varied, and custom microporous membranes are placed for continued growth due to their swiftness in personalized medicine.

Automation and implementation of multiple processes are leading to new product developments. Manufacturers are aiming to automate molecular processes to the same level of automation achieved for clinical chemistry. Key Companies such as BD Diagnostics, Roche Diagnostics, and Hologic (Gen-Probe) have developed and introduced automated molecular platforms that integrate both analytical and pre-analytical processes. Automation in the diagnostics has led to the quicker analysis and few errors in less time and also reduced the requirement of a number of lab scientists. In the past, vitro diagnostics were only available in the clinical setting. However, this trend is changing with the increasing development of advanced devices such as home care tests and point of care systems, which offer instant results. More advanced diagnostics were developed, which require only a single drop of blood, urine, or saliva to perform diagnosis and interpret diseases within minutes.

Increasing price pressures and low budgets, and lower reimbursements are the market restraints that hampering the growth of the market. Poor reimbursement policies for diagnostic testing is hampering the growth of the IVD market Globally. Reimbursement policies for diagnostic testing are not the same across geographies and are moving in a downward trend. Hospitals and diagnostic laboratories are forced to reduce their expenditure on IVD instruments to have even or profitable revenue. Lowered reimbursement and payment for a few instruments like SMBG in European countries like Germany and the UK have reduced the SMBG segment growth. Reduction of reimbursement by Medicare for IVD instruments is limiting the demand for certain diagnostic testing across all segments.
Global In-Vitro Diagnostics Market Segmentation Analysis
Based on technique, the global market for in-vitro diagnostics is broadly segmented as immunoassays, POC diagnostics, molecular diagnostics, haematology, tissue diagnostics, microbiology, self-blood-glucose monitoring, and others. By-products, the global market for in-vitro diagnostics is classified into instruments, reagents, and data management system.

On the basis of application, the global market for in-vitro diagnostics is divided into infectious diseases, diabetes, cancer/oncology, cardiology, autoimmune diseases, nephrology, drug testing, and others. The global Infection diseases diagnostics market was worth US$ 24.94 billion in 2018 and is expected to reach US$ XX billion by 2026 at a CAGR of XX% during the forecast period 2019-2026. Infection diseases diagnostics segment occupied the largest market share in 2018. Infectious diseases are disorders caused by organisms such as bacteria, viruses, fungi or parasites. Infectious diseases include HIV, Hepatitis, and other diseases. HIV is considered as one a major global public health issue. In 2017, 940,000 people died from HIV-related causes globally. According to the World health organization (WHO), the African region is the most affected region, with an HIV prevalence of 25.7 million in 2017. The African region also accounts for over two-thirds of the global total of new HIV infections. This will grow the in vitro diagnostics market in Africa.

For instance, In October 2018, South Korean biotech company Bioneer Corp. received the CE-IVD mark for its quantity analysis kit for human immunodeficiency virus-1 from Europe.

Based on end user, the global market for in-vitro diagnostics is categorized as laboratories, hospitals, academics, and others. Among all end-users, hospitals and laboratories occupied a majority of the market share with 47% and 26% respectively in 2018. The IVD market in hospitals segment was valued at US$ 27.59 billion in 2018 and is estimated to reach US$ XX billion by 2026 with a CAGR of XX% during the forecast period. Hospitals and diagnostic laboratories services are an integral part of disease diagnosis, treatment, monitoring response to treatment, disease surveillance programs and clinical research. Laboratories segment accounted for the second largest share in the market. The number of patients is very high in hospitals and to reduce the turnaround time, cost and manpower the hospitals refer the few complicated tests to the reference laboratories who can manage the high-test volume with advanced instruments and specific laboratory technicians.
Global In-Vitro Diagnostics Market Regional Analysis
The global In-Vitro Diagnostics Market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.
North America In-Vitro Diagnostics market is estimated to reach US$ XX billion by 2026 from the initial value of US$ 21.54 billion in 2018. The market is growing at a CAGR of XX% during the forecast period from 2018 to 2026. North America is one of the major regions for IVD Diagnostics market. The US holds the majority of share with 91% of the total regional market followed by Canada and Mexico with XX% and XX% respectively. The IVD instruments market in North America is witnessing significant growth, primarily because of the growing ageing population as well as the high prevalence of chronic and infectious diseases. Additionally, the increased awareness among the population has resulted in most people in the US having regular tests and check-ups, which has increased the sales of IVD products in the country.
Among the Middle East and Africa, Saudi Arabia IVD market in 2018 is estimated to be around USD XX million, for the year 2018 and expected to grow at CAGR of about 7.8% over the forecast period. Also Africa IVD market would reach the market size by 1.9X by 2026. Furthermore, China is the fastest growing market among all the Asia Pacific countries.
Global In-Vitro Diagnostics Company Trends
Some of the key market players are BioMérieux, Danaher Corporation, Roche Diagnostics, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Abbott Laboratories, Bayer AG, Arkray, Inc., Sysmex Corporation, Johnson & Johnson and Siemens AG.
Danaher and Abbott Laboratories are estimated to have the same or slightly higher market share in 2022 while the rest of the top eight companies will see a slight decline in market share. Siemens will have the highest decline of the market share of around two followed by Roche with 1%.
The companies are heavily investing in the market to develop new products and are collaborating and acquiring other companies which help in increasing their market share and will also strengthen the R & D
New product launches, partnerships, and acquisitions are few on the major strategies adopted by the leading companies in the industry. For instance, May 03, 2018, bioMérieux launched ENDOZYME II GO, a new endotoxin test in the bioMérieux ENDONEXT range of recombinant horseshoe crab Factor C (RFC) assays. This new assay results from the combined expertise of bioMérieux in microbiology and Hyglos GmbH in endotoxin detection enables endotoxin testing in pharmaceutical grade water, injectable drugs, and other pharmaceutical products.

Read more information about Global In-Vitro Diagnostics Market - https://www.datamintelligence.com/research-report/in-vitro-diagnostics-market

About DataM Intelligence
DataM Intelligence 4Market Research is a Market Intelligence and Business Research firm, based in India. It aims to bridge the two main aspects of a business decision - opinion and supportive data.

Market Research for long has been losing its credibility owing to low reliability and high proportions of estimations. Having identified this gap, DataM was established to provide businesses with reliable and near-market intelligence. Reporting the actual market scenario has been made possible by our proprietary methodology, that essentially revolves around gathering inputs from industry participants and integrating the trends into statistical Databank. This approach not only aligns the findings with historical data but also allows a highly justifiable forecast model.

Corporate Address
1st floor, Phoenix Tech Tower, Plot no: 14/46, Habsidguda, IDA-Uppal, Hyderabad-500039, Telangana

Email
info@datamintelligence.com

Phone
+1 877-441-4866

This release was published on openPR.